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Biomarker Proﬁles in Heart Failure Patients With Preserved and
Reduced Ejection Fraction
Jasper Tromp, MD;* Mohsin A. F. Khan, PhD;* IJsbrand T. Klip, MD; Sven Meyer, MD; Rudolf A. de Boer, MD, PhD; Tiny Jaarsma, RN, PhD;
Hans Hillege, PhD; Dirk J. van Veldhuisen, MD, PhD; Peter van der Meer, MD, PhD; Adriaan A. Voors, MD, PhD
Background-—Biomarkers may help us to unravel differences in the underlying pathophysiology between heart failure (HF) patients
with a reduced ejection fraction (HFrEF) and a preserved ejection fraction (HFpEF). Therefore, we compared biomarker proﬁles to
characterize pathophysiological differences between patients with HFrEF and HFpEF.
Methods and Results-—We retrospectively analyzed 33 biomarkers from different pathophysiological domains (inﬂammation,
oxidative stress, remodeling, cardiac stretch, angiogenesis, arteriosclerosis, and renal function) in 460 HF patients (21% HFpEF, left
ventricular ejection fraction ≥45%) measured at discharge after hospitalization for acute HF. The association between these
markers and the occurrence of all-cause mortality and/or HF-related rehospitalizations at 18 months was compared between
patients with HFrEF and HFpEF. Patients were 70.611.4 years old and 37.4% were female. Patients with HFpEF were older, more
often female, and had a higher systolic blood pressure. Levels of high-sensitive C-reactive protein were signiﬁcantly higher in
HFpEF, while levels of pro-atrial-type natriuretic peptide and N-terminal pro-brain natriuretic peptide were higher in HFrEF. Linear
regression followed by network analyses revealed prominent inﬂammation and angiogenesis-associated interactions in HFpEF and
mainly cardiac stretch–associated interactions in HFrEF. The angiogenesis-speciﬁc marker, neuropilin and the remodeling-speciﬁc
marker, osteopontin were predictive for all-cause mortality and/or HF-related rehospitalizations at 18 months in HFpEF, but not in
HFrEF (P for interaction <0.05).
Conclusions-—In HFpEF, inﬂammation and angiogenesis-mediated interactions are predominantly observed, while stretch-
mediated interactions are found in HFrEF. The remodeling marker osteopontin and the angiogenesis marker neuropilin predicted
outcome in HFpEF, but not in HFrEF. ( J Am Heart Assoc. 2017;6:e003989. DOI: 10.1161/JAHA.116.003989.)
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T he difference in pathophysiology between heart failurewith a reduced ejection fraction (HFrEF) and heart failure
with a preserved ejection fraction (HFpEF) remains poorly
understood, and effective treatment options are currently not
available for HFpEF.1–4 Therefore, a better understanding of
the pathophysiology of HFpEF is required, which eventually
may help to improve outcome.
Patient-speciﬁc biomarker proﬁles are useful for the
purpose of monitoring disease severity and progression, to
guide therapy, but also for characterizing the pathophysiology
of HF.5–9 We hypothesize that differences in biomarker levels
and correlative associations between HFrEF and HFpEF may
provide important insights into speciﬁc activities of patho-
physiological processes.5–9
The aim of this study was to characterize HFpEF and HFrEF
using a network analysis on an extensive set of 33 biomarkers
of various pathophysiological pathways. Therefore, we inves-
tigated differences in biomarker levels, patterns of
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correlations, and predictive value of biomarkers in patients
with HFpEF and HFrEF.
Methods
Study Design and Population
Measurements of biomarkers were performed in a subcohort
of the Coordinating study evaluating Outcomes of Advising
and Counseling in Heart failure (COACH) trial of which
rationale, design, and results have been previously
described.10,11 In short, the COACH trial studied the effects
of additional intensive nurse-led support on the prognosis of
1023 chronic HF patients. A hospital admission for HF (NYHA
II-IV) inclusion criteria for the COACH trial included and
patients had to be at least 18 years of age. Patients were
excluded if they underwent an intervention (percutaneous
transluminal coronary angioplasty, coronary artery bypass
graft, heart transplantation, valve replacement) in the previous
6 months or if they had a planned intervention in the following
3 months. Additionally, patients were excluded if they had an
ongoing evaluation for heart transplantation.10 Left ventricular
ejection fraction (LVEF) measurements were available in 832
patients. Biomarkers were measured in blood collected from
460 patients shortly before discharge between 8:00 AM and
4:00 PM, after patients had been clinically stabilized and were
considered well enough to go home. Baseline characteristics
of the current substudy were comparable to the entire COACH
study (Table S1). The study complies with the Declaration of
Helsinki, local medical ethics committees approved the study,
and all patients provided written informed consent.
Study and Laboratory Measurements
HFpEF was deﬁned as having a LVEF ≥45%, measurements of
high-sensitive C-reactive protein (hs-CRP), pentraxin-3, growth
differentiation factor, soluble receptor of advanced glycation
end-products, interleukin-6, tumor necrosis factor a, tumor
necrosis factor–associated receptor 1 a, myeloperoxidase,
syndecan-1, periostin, ST-2, osteopontin, pro-atrial-type natri-
uretic peptide (proANP), vascular endothelial growth factor
receptor (VEGFR), angiogenin, end-terminal pro c-type natri-
uretic peptide, neuropilin-1, endothelial cell-selective adhe-
sion molecule, neutrophil gelatinase-associated lipocalin,
d-dimer, WAP 4-disulﬁde core domain protein HE4, mesothe-
lin, polymeric immunoglobulin receptor, prosaposin, and TROY
were measured by Alere San Diego, Inc, (San Diego, CA),
using enzyme-linked immunosorbent assays. Immunoassays
to ST2 were developed by Alere. This research assay by Alere
has not been standardized to the commercialized assays used
in research or in clinical use. Furthermore, the extent to which
this Alere assay correlates with the commercial assay is not
fully characterized. Galectin-3 was measured using ELISA by
BG Medicine, Inc. (Waltham, MA). Transforming growth factor-
b and VEGF were analyzed using a quantitative multiplexed
sandwich ELISA system, SearchLightw proteome arrays
(Aushon BioSystems, Billerica, MA). N-terminal pro-brain
natriuretic peptide (NT-proBNP) was measured using the
Elecsys proBNP ELISA by Roche Diagnostics (Mannheim,
Germany). Erythropoietin a was measured using the IMMU-
LITEw erythropoietin ELISA by Diagnostic Products Corpora-
tion (Los Angeles, CA). Inter- and intra-assay coefﬁcients of
the assays used can be found in Table S2. Endothelin-1,
interleukin-6, and cardiac-speciﬁc troponin I were measured
in frozen plasma samples collected at baseline using high-
sensitive single molecule counting (SMC
TM) technology (RUO,
Erenna Immunoassay System; Singulex Inc, Alameda, CA).
Estimated glomerular ﬁltration rate was based on the
simpliﬁed Modiﬁcation of Diet in Renal Disease.12
Study End Points
For studying the relationship between biomarker levels and
outcome, the primary end point of the COACH trial was used.
This end point is a combined end point consisting of all-cause
mortality and/or HF-related rehospitalizations at 18 months.
An independent end point committee adjudicated the end
point.
Statistical Analysis
Continuous variables are presented as medians with
interquartile range or meansSD where appropriate. Cate-
gorical variables are presented as numbers with percentages.
Baseline characteristics and biomarker concentrations at
baseline were stratiﬁed according to HFrEF and HFpEF.
Intergroup differences were tested using Student t test or
Mann–Whitney U test for continuous variables or v2 test for
categorical variables. Principal component (PC) analysis was
performed to correct for multiple comparisons with HFrEF and
HFpEF as categorical variables, using an established statis-
tical method described elsewhere.13 This method is often
used in -omics based studies, where there is a natural
correlation between markers because of the fact that these
often belong to similar pathophysiological processes.14
Indeed, also for the 33 biomarkers employed in this study,
biomarkers are clearly interrelated, belonging to several
similar pathophysiological processes (Figure 1). In this situ-
ation the Bonferroni correction can be considered too
conservative.15 Here, the PC-based correction has been
suggested to be more effective.14,15 Additionally, this method
has been previously successfully used in correcting for
multiple comparisons in pairwise correlations.13 A total of
21 PCs, of which the eigenvalues cumulatively explained
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>95% of the variation observed in the data set when
comparing HFrEF with HFpEF, were found. The corrected
signiﬁcance level for multiple testing was thus set at P<0.05/
21, equating to an adjusted P-value cut-off of 0.00238. To
correct for multiple comparison for interbiomarker correla-
tions, 0.05/[PC9(PC1)/2] was used for the adjusted P cut-
off value, where PC is the number of principal components
found. To study the inﬂuence of clinical confounders on
biomarker-level differences between HFrEF and HFpEF, logis-
tic regression was performed. Here, HFpEF is coded as 1 and
HFrEF as 0. An odds ratio above 1 signiﬁes that higher levels
are associated with HFpEF. Associations were corrected for
age, sex, estimated glomerular ﬁltration rate, a history of
diabetes mellitus, and other clinical covariates that signiﬁ-
cantly differed between HFrEF and HFpEF. Next, a Spearman’s
rank correlation coefﬁcient was calculated for each possible
biomarker pair in the HFrEF cohort of patients and the
procedure was repeated for HFpEF. This resulted in 2 sets of
R-values with associated P-values for both HFrEF and HFpEF.
To adjust for multiple testing, only those correlations passing
the adjusted P-value cut-off calculated from the PC analysis
were deemed statistically signiﬁcant and subsequently
retained. These signiﬁcant correlation coefﬁcients for HFrEF
and HFpEF were then graphically displayed as heatmaps with
associated disease domains for all biomarkers. Network
analysis was performed to analyze associations between
biomarkers in HFrEF and HFpEF. First, all signiﬁcant associ-
ations found within HFrEF and HFpEF were separately
depicted as circular networks. Next, signiﬁcant associations
between biomarkers exclusive to HFrEF and HFpEF were
identiﬁed. To ascertain whether these associations were
signiﬁcantly different, the Fishers z-transformation test was
used to compare R-values between HFrEF and HFpEF. The P-
values from these associations were corrected using the PC
analysis method described above.
For outcome analysis, a univariable interaction test was
performed between the (log2-transformed) biomarker and HF
status (HFrEF versus HFpEF). The interaction test was then
bootstrapped with 1000 iterations to validate the results.
Following this, a multivariable interaction test was performed
correcting for the COACH risk engine. The COACH risk engine
includes sex, age, pulse pressure, diastolic blood pressure,
history of stroke, history of diabetes mellitus, estimated
glomerular ﬁltration rate, atrial ﬁbrillation, myocardial infarc-
tion, peripheral arterial disease, and levels of NT-proBNP and
sodium and is powered for the primary end point used in this
study, as published elsewhere.16 The relationship of the primary
end point with biomarkers, showing a signiﬁcant interaction
Figure 1. Heatmaps depicting correlation between biomarkers in HFrEF (A) and HFpEF (B). Biomarker correlations that did not pass the
corrected P-value (0.05/21) are black. Red entails a negative correlation, green entails a positive correlation. BUN indicates blood urea nitrogen;
CRP, C-reactive protein; EPO, erythropoietin; ESAM, endothelial cell-selective adhesion molecule; GDF-15, growth differentiation factor 15;
HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IL-6, interleukin 6; MPO,
myeloperoxidase; NGAL, neutrophil gelatinase-associated lipocalin; NT-proBNP, N-terminal pro-brain-type natriuretic peptide; NT-proCNP, amino
terminal pro-C-type natriuretic peptide; PIGR, polymeric immunoglobulin receptor; proANP, pro-atrial-type natriuretic peptide; PSAP, prostate-
speciﬁc acid phosphatase; RAGE, receptor of advanced glycation end-products; ST-2, suppression of tumorigenicity 2; TGF-b, transforming
growth factor b; TNF-a, tumor necrosis factor a; TNF-a-R1a, tumor necrosis factor a receptor 1a; VEGF, vascular endothelial growth factor;
VEGFR, vascular endothelial growth factor receptor; WAP4C, WAP 4 disulﬁde core domain protein.
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with HF status and outcome, was then graphically depicted
using Kaplan–Meier curves. To correct for potential optimism
and given the limited sample size, we bootstrapped the
estimates with 1000 iterations.17 The signiﬁcance of a differ-
ence between tertiles of biomarker levels and association with
outcome was tested using the Log-rank test. Univariable and
multivariable associations of biomarkers with outcome were
tested using the Cox regression. Tests performed were 2-tailed
and a P-value of <0.05 was considered statistically signiﬁcant.
All statistical analyses were performed using STATA version
13.0 (StataCorp LP, College Station, TX) and R, version 3.2.3.
Results
Patient Characteristics
The 460 patients in this cohort had a mean age of
70.611.1 years and 37.4% were female. Most patients
were in NYHA class III (52%) with a mean LVEF of 32.514.0%
(Table 1). Ninety-six patients had HFpEF (21%). Patients with
HFpEF in this cohort were relatively older (74.5 years versus
69.6 years, P<0.001) and more often female (51.0% versus
33.8%, P=0.002). Additionally, patients with HFpEF were
found to have a higher systolic blood pressure (126.6 mm Hg







LVEF (%) 32.514.0 26.78.5 54.47.5 NA
Demographics and HF characteristics
Age, y 70.611.1 69.6 (11.2) 74.5 (10.0) <0.001*
Female sex, n (%) 172 (37.4%) 123 (33.8%) 49 (51.0%) 0.002*
NYHA class (at discharge) II/III/IV, % 44/52/4 42/54/4 55/41/4 0.064
Previous HF hospitalization, n (%) 155 (33.7%) 118 (32.4%) 37 (38.5%) 0.260
Clinical signs
BMI, kg/m2 27.05.6 26.85.5 28.05.7 0.08
Systolic BP, mm Hg 117.921.3 115.620 126.623.1 <0.001*
Diastolic BP, mm Hg 68.912.3 68.912.4 68.912.1 0.980
eGFR, mL/min per 1.73 m2 54.920.5 55.120.4 53.821.1 0.580
Heart rate, bpm 74.213.4 74.713.8 72.211.8 0.110
Medical history, n (%)
Myocardial infarction 187 (40.7%) 161 (44.2%) 26 (27.1%) 0.002*
Hypertension 191 (41.5%) 143 (39.3%) 48 (50.0%) 0.058
Diabetes mellitus 135 (29.3%) 104 (28.6%) 31 (32.3%) 0.048*
COPD 130 (28.3%) 99 (27.2%) 31 (32.3%) 0.320
Atrial fibrillation/flutter 209 (45.4%) 159 (43.7%) 50 (52.1%) 0.140
Anemia 128 (27.8%) 92 (25.3%) 36 (37.5%) 0.017*
Medication, n (%)
ACE-inhibitor/ARB 378 (82.2%) 311 (85.4%) 67 (69.8%) <0.001*
b-Blocker 312 (67.8%) 255 (70.1%) 57 (59.4%) 0.005*
Diuretic 440 (95.7%) 350 (96.2%) 90 (93.8%) 0.300
Statin 183 (39.8%) 153 (42.0%) 30 (31.2%) 0.055
Digoxin 155 (33.7%) 120 (33.0%) 35 (36.5%) 0.052
Laboratory
Hemoglobin, g/dL 8.5 (7.7, 9.2) 8.6 (7.8, 9.3) 8.1 (7.2, 8.8) <0.001*
Sodium, mEq/L 138.64.3 138.64.4 138.64.2 0.973
Potassium, mEq/L 4.2 (3.9, 4.6) 4.3 (3.9, 4.6) 4.1 (3.7, 4.6) 0.214
ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; BP, blood pressure; COPD, chronic obstructive pulmonary disease; eGFR,
estimated glomerular ﬁltration rate; HF, heart failure; HFpEF, heart failure with a preserved ejection fraction; HFrEF, heart failure with a reduced ejection fraction; LVEF, left ventricular
ejection fraction; NA, not available; NYHA, New York Heart Association.
*P-value lower than the signiﬁcance treshhold of 0.05.
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versus 115.6 mm Hg, P<0.001) compared to patients with
HFrEF. Furthermore, patients with HFpEF used fewer
angiotensin-converting enzyme inhibitors (55.2% versus
76.9%, P<0.001) and b-blockers (59.4% versus 70.1%,
P<0.001) at discharge.
Biomarker Levels in HF With Reduced and
Preserved Ejection Fraction
PC analysis revealed 21 principal components that accounted
for a cumulative proportion of variance of 95% between HFrEF
and HFpEF, which were subsequently used for adjusting the P-
value signiﬁcance threshold (P<0.05/21; Figure S1). Table 2
shows the baseline biomarker concentrations stratiﬁed
according to HFrEF and HFpEF where P-values shown are
corrected for multiple testing. Levels of hs-CRP were higher in
HFpEF (3.6 mg/L versus 2.1 mg/L, P=0.001) and levels of
pentraxin-3 were higher in HFrEF (3.9 ng/mL versus 3.2 ng/
mL, P=0.009). Levels of cardiac stretch markers NT-proBNP
(2988 pg/mL versus 1948 pg/mL, P<0.001) and proANP
(21.9 pg/mL versus 17.0 pg/mL) were higher in HFrEF.
Additionally, the angiogenesis-speciﬁc marker VEGFR
(0.8 ng/mL versus 0.7 ng/mL, P=0.009) was higher in
HFrEF. After adjusting for multiple comparisons, levels of
hs-CRP (P=0.022) remained signiﬁcantly higher in HFpEF,
while the cardiac stretch markers NT-proBNP (P<0.001) and
proANP (P=0.042) remained signiﬁcantly higher in HFrEF.
Biomarker associations with HFrEF and HFpEF are shown
in Table S3. When correcting for clinical covariates (age, sex,
estimated glomerular ﬁltration rate, systolic blood pressure, a
history of myocardial infarction; diabetes mellitus; atrial
ﬁbrillation and anemia), higher levels of hs-CRP (odds ratio:
1.29; 95% CI 1.09–1.52, P=0.003) remained associated with
HFpEF, while higher levels of NT-proBNP (odds ratio: 0.68;
95% CI 0.57–0.82, P<0.001) and proANP (odds ratio: 0.69;
95% CI 0.53–0.88, P=0.003) remained associated with HFrEF.
After additionally correcting for b-blocker and angiotensin-
converting enzyme inhibitor/angiotensin II receptor blocker
use, the statistical associations for these 3 markers remained
(Table S3).
Biomarker Associations and Network Analysis
Heatmaps for the association between biomarkers in HFrEF
and HFpEF are depicted in Figure 1. Figure 2 shows the
graphical depiction of biomarker networks in HFrEF and
HFpEF. Results from the correlation analysis and associated
heatmaps reveal that correlations between biomarkers in
HFpEF are more associated with remodeling and inﬂamma-
tion, while in HFrEF angiogenesis is a more prominent feature
(Figure 1). Network analysis further showed myeloperoxidase
to be involved in interactions in both HFrEF and HFpEF.
Additionally, renal marker neutrophil gelatinase-associated
lipocalin and blood urea nitrogen as well as inﬂammation
marker receptor of advanced glycation end-products were
involved in biomarker associations in HFpEF.
When examining the exclusive interactions between
biomarkers in HFrEF and HFpEF, HFpEF revealed interactions,
which were mainly associated with inﬂammation (interleukin-
6; pentraxin-3; Table 3, corrected P-value for difference
<0.05). In contrast, HFrEF showed exclusive interactions that
were NT-proBNP mediated (Table 3), indicating that biomar-
ker interactions are more associated with cardiac stretch in
HFrEF and inﬂammation in HFpEF. In sensitivity analysis with
a deﬁnition of HFrEF at LVEF ≤40% and a deﬁnition of HFpEF
at LVEF ≥50%, exclusive associations in HFpEF remained
inﬂammation mediated, while NT-proBNP mediated associa-
tions in HFrEF (Table S4).
Outcome
Of the total cohort, 41% reached the clinical end point of
death and/or HF rehospitalization (41% HFrEF versus 44.8%
HFpEF, P=0.659, Figure S2). NT-proBNP was found to be
equally predictive in HFrEF and HFpEF (Table S5). A signiﬁcant
interaction in both univariable and multivariable analysis was
found for HF status and neuropilin as well as osteopontin
(both P<0.05). Both biomarkers were found only to be
predictive in HFpEF (Figures 3 and 4, Table S5). Interaction
between neuropilin (P=0.007) and osteopontin (P=0.018) and
HF status for the primary end point remained following
sensitivity analysis for a deﬁnition of HFpEF of LVEF ≥50%.
After bootstrapping with 1000 iterations, the interaction with
HF status for the primary end point stayed signiﬁcant for both
osteopontin (P=0.002) and neuropilin (P=0.011) in univariable
analyses. Also in multivariable analyses, the interaction
remained signiﬁcant for osteopontin (P=0.016) and neuropilin
(P=0.015).
When examining the relationship with HF rehospitalizations
and all-cause mortality separately in univariable analysis, we
see that osteopontin is predictive for both HF rehospitalizations
(P=0.007) and all-cause mortality (P=0.031) separately, but not
in HFrEF (Figures S3 and S4). Neuropilin was predictive in
univariable analysis for all-cause mortality in both HFrEF
(P=0.003) and HFpEF (P=0.023). However, neuropilin was only
predictive of HF rehospitalizations in HFpEF (P=0.026) and not
in HFrEF (P=0.026) (Figures S5 and S6).
Discussion
In this study, we demonstrate a distinct biomarker proﬁle for
HFpEF and HFrEF patients by using a novel approach
employing network analysis to identify exclusive interactions
within the 2 disease entities. Higher levels of Hs-CRP and
DOI: 10.1161/JAHA.116.003989 Journal of the American Heart Association 5






















Table 2. Baseline Markers Stratiﬁed to HFrEF and HFpEF
Total Cohort (n=460) HFrEF (n=364) HFpEF (n=96) P Value P Value*
Inflammation
hs-CRP, mg/L 2.3 (0.9, 5.2) 2.1 (0.8, 4.7) 3.6 (1.8, 7.0) 0.001† 0.022†
Pentraxin-3, ng/mL 3.7 (2.5, 5.6) 3.9 (2.7, 5.8) 3.2 (2.4, 4.7) 0.009† 0.198
GDF-15, ng/mL 2.8 (1.9, 4.2) 2.8 (1.9, 4.3) 2.6 (1.9, 4.1) 0.670 1.000
RAGE, ng/mL 2.9 (1.9, 4.8) 3.0 (1.9, 4.9) 2.6 (1.7, 4.0) 0.053 1.000
IL-6, pg/mL 7.0 (3.7, 12.2) 6.7 (3.6, 11.3) 8.2 (4.5, 13.6) 0.100 1.000
TNF-a, pg/mL 47.9 (6.2, 119.4) 47.3 (8.1, 109.5) 56.7 (4.8, 194.4) 0.350 1.000
TROY, ng/mL 0.9 (0.7, 1.5) 0.9 (0.7, 1.4) 0.9 (0.6, 1.6) 0.540 1.000
TNF-a-R1a, ng/mL 3.0 (2.1, 4.5) 3.0 (2.1, 4.4) 3.1 (2.2, 4.9) 0.490 1.000
Oxidative stress
MPO, ng/mL 20.4 (15.6, 28.2) 20.6 (15.6, 28.4) 19.9 (15.2, 27.2) 0.530 1.000
Remodeling
Syndecan-1, ng/mL 20.2 (14.1, 27.5) 20.5 (14.1, 28.1) 19.2 (14.0, 24.6) 0.360 1.000
Periostin, ng/mL 4.6 (3.4, 6.6) 4.7 (3.4, 6.6) 4.5 (3.4, 6.6) 0.520 1.000
Galectin-3, ng/mL 19.9 (15.2, 25.7) 20.0 (14.8, 25.9) 19.3 (15.8, 25.3) 0.960 1.000
ST-2, ng/mL 2.5 (1.4, 5.6) 2.4 (1.4, 5.5) 3.1 (1.6, 6.2) 0.140 1.000
Osteopontin, ng/mL 160.1 (108.8, 219.5) 161.2 (108.4, 217.1) 153.8 (110.7, 240.5) 0.980 1.000
TGF-ß, ng/mL 50.6 (34.4, 75.1) 51.4 (35.3, 77.5) 44.3 (30.9, 63.3) 0.069 1.000
Cardiomyocyte stretch
NT-proBNP, pg/mL 2601 (1398–5989) 2988.8 (1511.0, 6708.9) 1948.0 (855.3, 3827.0) <0.001† <0.001†
proANP, ng/mL 20.4 (12.1–33.3) 21.9 (13.2, 35.4) 17.0 (10.0, 28.2) 0.002† 0.042†
cTnI, pg/mL 14.1 (7.3, 29.4) 13.1 (5.8, 34.8) 0.562 1.000
Angiogenesis
VEGF, pg/mL 62.8 (31.4, 148.7) 62.5 (28.5, 139.9) 63.0 (35.8, 162.9) 0.280 1.000
VEFGR, ng/mL 0.8 (0.6, 1.0) 0.8 (0.6, 1.1) 0.7 (0.5, 1.0) 0.009† 0.255
Angiogenin, lg/mL 5.0 (3.5, 7.4) 5.0 (3.5, 7.5) 5.2 (3.5, 7.3) 0.840 1.000
NT-proCNP, ng/mL 0.024 (0.017, 0.035) 0.023 (0.017, 0.034) 0.024 (0.015–0.037) 0.440 1.000
Neuropilin-1, ng/mL 10.0 (7.1, 13.7) 10.1 (7.1, 14.0) 9.6 (7.0, 13.5) 0.770 1.000
Arteriosclerosis
ESAM, ng/mL 52.9 (44.5, 64.4) 53.8 (45.3, 64.8) 50.2 (41.1, 63.2) 0.065 1.000
Renal function
NGAL, ng/mL 84.6 (60.4, 119.9) 84.2 (59.4, 119.2) 84.7 (63.3, 122.3) 0.440 1.000
BUN, mmol/L 11.0 (8.2, 15.5) 10.7 (8.3, 15.6) 11.1 (7.7, 15.1) 0.650 1.000
Hematopoiesis
EPOa, IU/L 9.6 (5.1, 15.9) 9.5 (5.0, 15.5) 10.3 (5.2, 16.5) 0.560 1.000
Other
D-Dimer, lg/mL 0.5 (0.2, 1.1) 0.5 (0.2, 1.1) 0.6 (0.2, 1.0) 0.710 1.000
WAP4C, ng/mL 5.7 (3.1, 10.1) 5.8 (3.5, 10.0) 5.3 (3.1, 10.3) 0.910 1.000
Mesothelin, ng/mL 29.4 (22.8, 38.7) 29.8 (22.9, 38.8) 28.3 (22.5, 38.0) 0.380 1.000
PIGR, ng/mL 600.6 (337.4, 952.0) 609.0 (388.7, 952.0) 598.7 (331.5, 943.0) 0.330 1.000
PSAP, ng/mL 68.6 (49.2, 98.5) 68.8 (49.8, 101.0) 67.3 (48.0, 93.6) 0.760 1.000
ET-1, ng/mL 4.5 (3.6, 6.1) 4.5 (3.6, 6.1) 4.5 (3.4, 5.7) 0.430 1.000
BUN indicates blood urea nitrogen; cTNI, cardiac troponin-I; EPOa, erythropoietin; ESAM, endothelial cell-selective adhesion molecule; ET-1, endothelin-1; GDF-15, growth differentiation
factor 15; HFpEF, heart failure with a preserved ejection fraction; HFrEF, heart failure with a reduced ejection fraction; hs-CRP, high-sensitive C-reactive protein; IL-6, interleukin 6; MPO,
myeloperoxidase; NGAL, neutrophil gelatinase-associated lipocalin; NT-proBNP, N-terminal pro-brain-type natriuretic peptide; NT-proCNP, amino terminal pro-C-type natriuretic peptide;
PIGR, polymeric immunoglobulin receptor; proANP, pro-atrial-type natriuretic peptide; PSAP, prostate-speciﬁc acid phosphatase; RAGE, receptor of advanced glycation end-products; ST-2,
suppression of tumorigenicity 2; TGF-b, transforming growth factor b; TNF-a, tumor necrosis factor a; TNF-a-R1a, tumor necrosis factor a receptor 1a; VEGF, vascular endothelial growth
factor; VEGFR, vascular endothelial growth factor receptor; WAP4C, WAP 4 disulﬁde core domain protein.
*Corrected P-value. †P-value lower than the signiﬁcance treshhold of 0.05.
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lower levels of cardiac stretch markers NT-proBNP and pro-
ANP are found in HFpEF, which conﬁrm previous studies.8,18
Furthermore, exclusive interactions between biomarkers in
HFpEF were found to be associated with inﬂammation and
angiogenesis. In contrast, HFrEF showed exclusive interac-
tions associated with NT-proBNP. This is the ﬁrst study
reporting on exclusive interactions between biomarkers in
HFrEF and HFpEF. Additionally, this study showed for the ﬁrst
time that angiogenesis marker neuropilin and remodeling
marker osteopontin have exclusive predictive value for clinical
outcome in HFpEF.
Levels of hs-CRP were found to be higher in HFpEF patients
compared to HFrEF patients. Overall, reports with regard to
differences in association of CRP between HFrEF and HFpEF
have lacked consensus.8,19–21 Yet, patients included in the
previous studies were older and had relatively low levels of
NT-proBNP.8,19,20,22 Regardless of the difference in levels,
predictive value for hs-CRP was found to be limited in both
HFrEF and HFpEF after correction for a risk model in both this
and an earlier study.21 The cardiac stretch markers proANP
and NT-proBNP were found to be lower in HFpEF. This is the
ﬁrst study reporting differential levels of proANP in HFrEF and
HFpEF. The difference in levels of NTproBNP between HFrEF
and HFpEF conﬁrms earlier reports.8,18,23
A recent study used a similar network analysis approach.8
However, the number of biomarkers studied was limited and
no exclusive correlations were identiﬁed. When examining
exclusive correlations in HFpEF and HFrEF between biomark-
ers, we identiﬁed correlations that were inﬂammation and
angiogenesis associated in HFpEF, while correlations were
associated with NT-proBNP in HFrEF. The relatively strong
correlations between markers in both HFrEF and HFpEF
provide putative insights into possible differences at the
pathophysiological pathway level. For HFpEF, correlations
were found to be associated with interleukin-6 and pentraxin-
3. This is in line with earlier suggestions, in which a pro-
inﬂammatory state was proposed to underlie the pathophys-
iology of HFpEF.24–29 In contrast, exclusive interactions in
HFrEF were associated with NT-proBNP. As such, the
pathophysiology of HFrEF seems to be more associated with
cardiac stretch and oxidative stress.24 However, using
network analysis for determining underlying pathophysiolog-
ical differences between disease entities using biomarkers is
a relatively novel approach. Future studies should conﬁrm
A B
Figure 2. Network analysis depicting associations between biomarkers in HFrEF (A) and HFpEF (B). Associations shown are those that passed
the P-value cutoff (0.05/21). Node size and color are based on the clustering coefﬁcient. The edge betweenness was used as a criterion for the
edges. BUN indicates blood urea nitrogen; CRP, C-reactive protein; EPO, erythropoietin; ESAM, endothelial cell-selective adhesion molecule;
GDF-15, growth differentiation factor 15; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection
fraction; IL-6, interleukin 6; MPO, myeloperoxidase; NGAL, neutrophil gelatinase-associated lipocalin; NT-proBNP, N-terminal pro-brain-type
natriuretic peptide; NT-proCNP, amino terminal pro-C-type natriuretic peptide; PIGR, polymeric immunoglobulin receptor; proANP, pro-atrial-type
natriuretic peptide; PSAP, prostate-speciﬁc acid phosphatase; RAGE, receptor of advanced glycation end-products; ST-2, suppression of
tumorigenicity 2; TGF-b, transforming growth factor b; TNF-a, tumor necrosis factor a; TNF-a-R1a, tumor necrosis factor a receptor 1a; VEGF,
vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; WAP4C, WAP 4 disulﬁde core domain protein.
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these ﬁndings as well as combine them with data from
experimental studies to examine whether the pathophysio-
logical relationships found in clinical data also translate to
pathophysiological differences in an experimental setting.
Furthermore, most biomarkers are not cardiac exclusive.5 This
makes it relatively difﬁcult to discern whether biomarker
differences found in a clinical study are the cause or
consequence of HF. To optimize interpretability of biomarker
studies, future studies should be focused on biomarkers that
are highly cardiac speciﬁc. Secondly, when biomarker differ-
ences are found, experimental studies should validate the
ﬁndings and discern possible underlying pathophysiological
processes.
This study also showed differential association with
outcome of angiogenesis markers neuropilin and remodeling
marker osteopontin, which were both found to be more
predictive in HFpEF. Results with regard to differential
association with outcome should be interpreted in an
explanatory context of the pathophysiology, in which an
increase in levels of a certain biomarker can be detrimental in
1 disease entity and not necessarily in the other through
biological involvement or reﬂecting an underlying pathway.
Indeed, osteopontin was reported earlier to be involved in
prognosis in HF.30 However, a differential involvement
between HFrEF and HFpEF has not been previously reported.
Earlier experimental studies found a direct involvement of
osteopontin and cardiac remodeling, which in turn was found
to cause diastolic dysfunction.31
Neuropilin is identiﬁed as a coreceptor of vascular
endothelial growth factor receptor 2 (VEGFR-2).32 In a murine
model of cardiac pressure overload, animals that were
heterozygous for neuropilin showed higher mortality rates.33
This is the ﬁrst study reporting the predictive value of
neuropilin in HF for the combined end point. Here, we found






(Difference)R P Value* R P Value*
HFpEF
IL-6 D-Dimer 0.365 0.030† 0.149 1.000 0.001† 0.021†
Pentraxin-3 VEGF 0.344 0.029† 0.154 1.000 0.002† 0.043†
Periostin VEGF 0.438 0.001† 0.112 1.000 <0.001† 0.001†
NGAL PSAP-B1 0.396 0.010† 0.138 1.000 <0.001† 0.007†
HFrEF
NT-proBNP IL-6 0.135 1.000 0.363 <0.001† 0.001† 0.023†
NT-proBNP EPO-A 0.147 1.000 0.36 <0.001† 0.001† 0.025†
EPO-A indicates erythropoietin; HFpEF, heart failure with a preserved ejection fraction; HFrEF, heart failure with a reduced ejection fraction; IL-6, interleukin 6; NGAL, neutrophil gelatinase-
associated lipocalin; NT-proBNP, N-terminal pro-brain-type natriuretic peptide; PSAP, prostate-speciﬁc acid phosphatase; VEGF, vascular endothelial growth factor.
*Corrected P-value.
†P-value lower than the signiﬁcance treshhold of 0.05.
Figure 3. Kaplan–Meier curves depicting the relationship with outcome of osteopontin in tertiles, stratiﬁed to HFrEF and HFpEF. HFpEF
indicates heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
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that neuropilin was predictive of HF rehospitalizations in
HFpEF. Additionally, in multivariable analysis, neuropilin only
held predictive power in HFpEF. This suggests that neuropilin
is more reﬂective of HF severity in HFpEF and not in HFrEF.
Essentially, neuropilin is associated with angiogenesis. This
again emphasizes the importance of angiogenesis markers in
HFpEF compared to HFrEF.24
In earlier studies a signiﬁcant association between out-
come and HF status was found for end-terminal pro c-type
natriuretic peptide and galectin-3 with a deﬁnition of HFpEF of
LVEF >40%.34,35 These ﬁndings were conﬁrmed in this study.
Additionally, an earlier publication found signiﬁcant predictive
value of syndecan-1 in HFpEF but not in HFrEF.6 The fact that
no signiﬁcant interaction was found in this study for
syndecan-1 and the primary end point can potentially be
explained by the limited power of this study for HFpEF
patients at a deﬁnition of LVEF >45%, and the previous
publication for syndecan-1 corrected for a stepwise based
model for syndecan-1 instead of the COACH risk model.
The clinical implications of this study are 2-fold. First, this
study characterizes the underlying pathophysiology of
patients with HFpEF to be associated with inﬂammation and
endothelial function. This conﬁrms earlier studies with regard
to HFpEF and endorses the earlier proposed theory by Paulus
et al.24 Secondly, this study propagates a novel method for
utilizing network analysis to analyze a wide array of biomark-
ers in discerning the underlying pathophysiology of disease
entities in HF.8 This methodology provides a possible step
forward in dissecting the HF syndrome.5,36
Strengths and Limitations
The strengths of this study are the relatively high levels of NT-
proBNP of both the HFrEF and HFpEF patients and the large
number of available biomarkers. By having relatively high NT-
proBNP levels, the HFpEF patients in this study represent true
HF patients and have a relatively low number of false
positives. Secondly, the large number of biomarkers from
different disease domains available in this study provide for a
more unbiased approach towards discerning underlying
pathophysiological pathways.
However, the current analysis is a post-hoc analysis,
leading to a possible selection bias. Secondly, since patients
included are of European descent and relatively old, this limits
extrapolation to patients of different age and origin. Also,
pharmacological treatment during hospitalization might have
inﬂuenced biomarker levels and associations between HFrEF
and HFpEF. Furthermore, the choice for biomarkers was
restricted by limited baseline sample availability, with the
result that several interesting markers could not be studied.
Therefore, this study is not an exhaustive study of biomarker-
level differences in HFrEF and HFpEF and should be consid-
ered exploratory and hypothesis generating. Also, some of the
biomarkers measured had relatively high coefﬁcients of
variation. Therefore, some possible interesting interactions
and differences between biomarkers in HFrEF and HFpEF may
have been missed. Most importantly, results from this study
should be validated in a separate cohort.
The sampling of patients in COACH was performed at
discharge after recompensation. Since no data are available
on treatment during admission for HF previous to discharge,
this might confound some of the reported ﬁndings. In this
context, patients in the COACH trial cover a gray area
between acute decompensated and chronic HF patients. The
ﬁndings in this study should be regarded as explanatory in the
context of the pathophysiology of HFpEF and HFrEF, acting as
a stepping-stone for further research.
Conclusions
Biomarker levels differ in HFpEF and HFrEF, mainly in the
domains of cardiac stretch and inﬂammation. Interactions in
Figure 4. Kaplan–Meier curves depicting the relationship with outcome of neuropilin in tertiles, stratiﬁed to HFrEF and HFpEF. HFpEF
indicates heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
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HFpEF were found to be associated with inﬂammation and
angiogenesis, while interactions in HFrEF were associated
with cardiac stretch. The angiogenesis marker neuropilin and
remodeling marker osteopontin were found to only hold
predictive value in HFpEF, possibly reﬂecting underlying
pathophysiological processes. Results of this study should
be conﬁrmed in prospective biomarker studies.
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Table S1. Differences between entire cohort and subcohort 
 
  Total cohort (n=1023) Sub cohort (n=460) 
Treatment allocation     
   Control group  33 32,2 
   Basic support  33,3 32,4 
   Intensive support  33,6 35,4 
Demographics and clinical signs        
   Age (years)  70.8 ± 11 70.6 ± 11.1 
   Female sex (%)  37,5 37,4 
   BMI (kg/m2 26.9 ± 5.3 27.0 ± 5.6 
   Systolic BP (mmHg) 118.3 ± 21.0  117.9 ± 21.3 
   Heart rate (bpm)  74.6 ± 13.4 74.2 ± 13.4 
   LVEF (%)    33.7 ± 14.4 32.5 ± 14.0 
   Previous HF hospitalization  32,7 33,7 
   NYHA class, II/III/IV (%)  50.9/45.7/3.4 44/52/4 
Medical history (%)     
   Myocardial infarction  42,6 40,7 
   Stroke  16 14,8 
   Hypertension  42,9 41,5 
   Atrial fibrillation of flutter  44 45,4 
   Diabetes  29,3 29,3 
   COPD  26,2 28,3 
Laboratory     
   Hemoglobin (g/dL)    13.1 ± 2.0 13.2 ± 2.1 
   Sodium (mmol/L)    139 ± 4 138.6 ± 4.3 
   Creatinine (μmol/L)  125.0 ± 53 125.7 ± 52.8 
   eGFR (mL/min/1.73m2) 55.2 ± 21.1 54.9 ± 20.5 
   BUN (mmol/L)  10.7 (8.1 ‐ 15.2) 11.0 (8.2 - 15.5) 
Treatment at discharge (%)     
   ACE inhibitor or ARB  82,8 82,2 
   Beta blocker  66,2 67,8 
   Diuretic 95,8 95,7 
   MRA  54,1 56,3 
   Statin  37,9 39,8 
   Digoxin  30,2 33,7 
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; BP, blood pressure; COPD, 
chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HF, heart failure; HFpEF, heart failure with a preserved 














Table S2. Biomarker assay data.   
Biomarker Intra Assay %CV 
Inter Assay 
%CV Low Cutoff High Cutoff Units 
LTBR 13% 13% 0,028 45 ng/mL 
Mesothelin 12% 12% 6,1 120 ng/mL 
MPO 15% 14% 2 800 ng/mL 
Neuropilin 1 14% 15% 1 900 ng/mL 
Osteopontin 21% 22% 2,5 2500 ng/mL 
 Pentraxin 3 10% 11% 0,07 150 ng/mL 
Periostin 12% 12% 2,3 1921 ng/mL 
PIGR 16% 16% 12 2341 ng/mL 
PSAP-B 14% 16% 2 530 ng/mL 
ST-2 9% 10% 0,28 380 ng/mL 
Syndecan-1 25% 24% 2,4 393 ng/mL 
TNFR1A 11% 13% 0,025 68 ng/mL 
Troy 15% 14% 0,044 87 ng/mL 
RAGE 9% 10% 0,019 85 ng/mL 
VEGFR1 13% 12% 0,38 195 ng/mL 
NTProCNP 11% 12% 0,003 9 ng/mL 
WAP4C 14% 14% 0,16 130 ng/mL 
ANP propeptide 29% 28% 1600 110000 pg/mL 
D-Dimer 9% 10% 0,028 26 ug/mL 
ESAM 9% 9% 0,5 110 ng/mL 
GDF-15 9% 10% 0,014 6,4 ng/mL 
 Angiogenin 18% 18% 170 40000 ng/mL 
 CRP 17% 16% 0,065 33 ug/mL 






off Inter assay coefficient of variation (%) 
IL-6 0.10 0.88 13 
cTNI 0.20 1000 10 
ET1 0.5 250 7 
 
BG 





(%) LoB LoD LoQ 
Measuring 
range 



















Hs-CRP (doubling) 1.25 (1.08-1.46) 0.003 
              Model 1 1.29 (1.09-1.52) 0.003 
              Model 2 1.28 (1.08-1.51) 0.004 
Pentraxin-3 (doubling) 0.74 (0.56-0.98) 0.037 
              Model 1 0.81 (0.60-1.09) 0.165 
              Model 2 0.83 (0.62-1.12) 0.212 
NT-proBNP (doubling) 0.75 (0.65-0.87) <0.001 
              Model 1 0.68 (0.57-0.82) <0.001 
              Model 2 0.74 (0.62-0.88) 0.001 
proANP (doubling) 0.72 (0.58-0.89) 0.002 
              Model 1 0.66 (0.51-0.85)  0.001 
              Model 2 0.69 (0.54-.0.89) 0.004 
VEGF (doubling) 1.09 (0.97-1.23) 0.159 
              Model 1 1.03 (0.90-1.18) 0.639 
              Model 2  1.05 (0.92-1.20) 0.442 
Model 1: age, sex, eGFR, systolic blood pressure, a history of myocardial infarction; diabetes; atrial fibrillation and anemia 
Model 2: Model 1+ ACE-inhibitors/ARB & Beta-blocker usage 
Abbreviations: Hs-CRP, high-senstive C-reactive protein; NT-proBNP, N-terminal pro-brain-type natriuretic peptide; Pro-ANP, pro-atrial-type 
natriuretic peptide; VEGF, vascular endothelial growth factor 
 







Table S4. Sensitivity analysis exclusive interactions 
    HFpEF HFrEF 
Biomarker R p-value* R p-value* 
HFpEF           
IL6 D-Dimer 0.361 0.63 0.158 0.840 
Pentraxin-3 VEGF -0.388 0.21 -0.157 1.000 
Periostin VEGF -0.476 <0.001 -0.102 1.000 
NGAL PSAP-B1 0.381 0.21 0.147 1.000 
HFrEF           
NT-proBNP IL6 0.204 1.000 0.378 <0.001 
NT-proBNP EPO-A 0.315 1.000 0.360 <0.001 
 
*corrected p-value 
Abbreviations: EPO-A, erythropoietin; HFpEF, heart failure with a preserved ejection fraction; HFrEF, heart failure with a reduced ejection 
fraction; IL-6, Interleukin 6; NGAL, neutrophil gelatinase-associated lipocalin; NT-proBNP, N-terminal pro-brain-type natriuretic peptide; 
PSAP, prostate-specific acid phosphatase; VEGF, vascular endothelial growth factor. 







Table S5. Relationship with outcome of biomarkers.  
 HFrEF (n = 364) HFpEF (n = 96) p-value
1 p-value2 
Inflammation HR (95%CI) p-value HR (95%CI) p-value    
   hs-CRP, (doubling) 0.98 (0.88-1.08) 0.684 1.00 (0.77-1.30) 0.982 0.615 0.638 
   Pentraxin-3, (doubling) 0.89 (0.71-1.12) 0.336 1.14 (0.73-1.77) 0.569 0.074 0.277 
   GDF-15, (doubling) 1.09 (0.81-1.48) 0.563 2.06 (1.16-3.65) 0.014 0.180 0.064 
   RAGE, (doubling) 1.05 (0.86-1.28) 0.629 1.34 (0.90-1.98) 0.147 0.174 0.451 
   Interleukin 6, (doubling) 1.00 (0.87-1.16) 0.943 1.68 (1.14-2.48) 0.008 0.136 0.014 
   TNF-α, (doubling) 1.01 (0.96-1.06) 0.707 0.97 (0.88-1.07) 0.580 0.282 0.610 
   TNF-α-R1a, (doubling) 1.31 (0.99-1.73) 0.057 1.47 (0.90-2.39) 0.120 0.666 0.653 
Oxidative stress        
   MPO, (doubling) 0.89 (0.74-1.08) 0.243 1.12 (0.70-1.79) 0.644 0.505 0.276 
Remodelling        
   Syndecan-1, (doubling) 1.01 (0.82-1.24) 0.955 1.38 (0.99-1.93) 0.059 0.244 0.163 
   Periostin, (doubling) 1.03 (0.80-1.33) 0.824 1.17 (0.76-1.79) 0.485 0.798 0.849 
   Galectin-3, (doubling) 0.86 (0.59-1.25) 0.425 2.57 (1.19-5.53) 0.016 0.070 0.026 
   ST-2, (doubling) 0.98 (0.86-1.11) 0.694 1.27 (0.96-1.67) 0.092 0.268 0.219 
   Osteopontin, (doubling) 0.90 (0.72-1.14) 0.398 1.60 (0.98-2.62) 0.062 0.004 0.009 
   TGF-ß, (doubling) 1.01 (0.91-1.13) 0.834 1.07 (0.89-1.28) 0.465 0.702 0.466 
Cariomyocyte stretch        
   NT-proBNP, (doubling) 1.28 (1.14-1.43) <0.001 1.42 (1.10-1.84) 0.007 0.417 0.605 
   proANP, (doubling) 1.02 (0.82-1.27) 0.840 1.23 (0.85-1.76) 0.268 0.364 0.437 
   TnI, (doubling) 1.16 (1.06-1.28) 0.001 1.07 (0.86-1.33) 0.532 0.347 0.269 
Angiogenesis        
   VEGF, (doubling) 0.88 (0.81-0.96) 0.004 1.13 (0.88-1.47) 0.326 0.273 0.080 
   VEFGR (doubling) 1.19 (0.94-1.51) 0.156 1.37 (0.93-2.01) 0.106 0.918 0.603 
   Angiogenin, (doubling) 0.89 (0.74-1.06) 0.195 0.67 (0.47-0.95) 0.026 0.139 0.156 
   NT-proCNP, (doubling) 0.96 (0.73-1.25) 0.749 1.69 (1.15-2.49) 0.007 0.232 0.042 
   Neuropilin-1 (doubling) 1.12 (0.85-1.48) 0.425 2.34 (1.40-3.90) 0.001 0.017 0.024 
Arteriosclerosis        
   ESAM, (doubling) 1.35 (0.79-2.29) 0.268 1.77 (0.85-3.71) 0.127 0.571 0.528 
Renal function        
   NGAL, (doubling) 0.95 (0.69-1.29) 0.729 0.84 (0.46-1.53) 0.569 0.702 0.884 
   BUN, (doubling) 0.91 (0.63-1.33) 0.632 1.03 (0.49-2.19) 0.929 0.673 0.816 
Haematopoiesis        
   EPOa, (doubling) 1.09 (0.96-1.24) 0.197 1.27 (1.00-1.62) 0.049 0.745 0.129 
Other        
   D-Dimer, (doubling) 1.09 (0.97-1.22) 0.132 1.31 (0.99-1.75) 0.056 0.452 0.331 
   WAP4C (doubling) 1.18 (0.93-1.50) 0.164 1.61 (1.09-2.37) 0.016 0.413 0.181 
   Mesothelin, (doubling) 1.19 (0.88-1.61) 0.258 0.93 (0.46-1.89) 0.841 0.569 0.803 
   PIGR (doubling) 1.03 (0.79-1.34) 0.825 1.79 (1.13-2.83) 0.013 0.207 0.101 
   PSAP (doubling) 1.24 (0.96-1.59) 0.099 1.26 (0.79-2.01) 0.324 0.786 0.844 
   ET-1, (doubling) 1.30 (0.93-1.80) 0.120 0.99 (0.46-2.13) 0.972 0.746 0.859 
   TROY (doubling) 0.98 (0.73-1.31) 0.868 1.63 (1.05-2.54) 0.030 0.351 0.101 
1. Univariable interaction p-value 
2. Multivariable interaction p-value 







Abbreviations: BUN, blood urea nitrogen; cTNI, cardiac troponin-I; EPOa, erythropoietin; ESAM, endothelial cell-selective adhesion molecule; 
ET-1, endothelin-1; GDF-15, growth differentiation factor 15; HFrEF, heart failure with a reduced ejection fraction ; HFpEF, heart failure with 
a preserved ejection fraction; hs-CRP, high-sensitive C-reactive protein; IL-6, Interleukin 6; MPO, myeloperoxidase; NGAL, neutrophil 
gelatinase-associated lipocalin; NT-proBNP, N-terminal pro-brain-type natriuretic peptide; NT-proCNP, amino terminal pro-C-type natriuretic 
peptide; PIGR, polymeric immunoglobulin receptor; Pro-ANP, pro-atrial-type natriuretic peptide; PSAP, prostate-specific acid phosphatase; 
RAGE, receptor of advanced glycation end-products; TGF-b, transforming growth factor beta; TNF-a, tumor necrosis factor alpha; TNF-aR1a, 
tumor necrosis factor alpha receptor 1a; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; 
































Figure S1. PCA analysis 
 
Principal Component Analysis – PCA plot illustrating the first two principal components, collectively accounting for 43.4% (PC1 accounting for 
30.8%, and PC2 for 12.6%) of the overall variance in the combined HFpEF and HFrEF biomarker measurements. The PCA was performed 
using HFpEF and HFrEF as categorical variables, where biomarker levels are displayed as red and blue for patients with HFpEF and HFrEF 





















Figure S2. Surival stratified according to HFrEF and HFpEF 
 







Figure S3. Osteopontin in HFrEF and HFpEF for HF related hospitalizations at 18 months. 
 
 







Figure S4. Osteopontin in HFrEF and HFpEF for all-cause mortality at 18 months. 
 
 







Figure S5. Neuropilin in HFrEF and HFpEF for HF related hospitalizations at 18 months. 
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